Value-based drug system proposed in UK
- Policy & Price. Gopal, Kevin // Pharmaceutical Executive;Aug99, Vol. 19 Issue 8, p30
Focuses on the renegotiation of the Pharmaceutical Price Regulation Scheme (PPRS) between the British government and the pharmaceutical industry. Price reduction of branded medicines; Measures that offset the price reduction in the PPRS; How the PPRS gave the government an economic opportunity.
- Government pushes for 2.5% cut in drug prices. // BMJ: British Medical Journal (International Edition);8/21/93, Vol. 307 Issue 6902, p464
Reports the pharmaceutical price regulation scheme of drugs in Great Britain. Aims of drug price reduction; Factors contributing to excess profits in the pharmaceutical industry; Recommendation on the improvement of prescribing practices among general practitioners.
- Report from: Philippines. Wan, Jane // Pharmaceutical Technology;Nov2009, Vol. 33 Issue 11, p18
The article presents the pharmaceutical market report for the Philippines. It states that the Philippine government has imposed a heartening 50 percent price cut on certain drugs for hypertension, diabetes, and amoebiasis with mandatory compliance to the Maximum Drug Retail Price (MDRP) system....
- PhRMA wins! Federal judge blocks Maine price control law, but drug program proceeds. // Medical Marketing & Media;Dec2000, Vol. 35 Issue 12, p20
Reports on a Maine federal court's issuance of a preliminary injunction sought by the Pharmaceutical Research and Manufacturers of America against the state's drug price control policy. Provisions of the price control law; Continuous implementation of other parts of the law not affected by the...
- The Great Pharmacy Rip-off. Ragg, Mark // Bulletin with Newsweek;12/08/98, Vol. 117 Issue 6152, p26
Presents information on the deal between the Australian government under Hawke and the Pharmacy Guild over the price charged to the public for prescription drugs. The government and the pharmacists agreeing that the public should pay more; Secrecy about the agreement; Details on the various...
- BIG PHARMA'S DRUG PROBLEM. Surowiecki, James // New Yorker;10/16/2000-10/23/2000, Vol. 76 Issue 31, p98
Focuses on the pharmaceutical industry of the United States and the role of the regulatory system in the high prices of drugs. Skill of the drug industry in protecting its patents; Formula for lowering drug prices; Reason for the existence of the patent system.
- Regulating the pharmaceutical industry. Maynard, Alan; Bloor, Karen // BMJ: British Medical Journal (International Edition);07/26/97, Vol. 315 Issue 7102, p200
Editorial. Discusses a voluntary scheme intended to regulate pricing policies of drugs in Great Britain. Negotiation of target profit sales from sales of drugs to the National Health Service; Evidence of the scheme's success; Conflict between attempts to control NHS expenditure and subsidy of...
- Delays in UK value-based pricing scheme a win for big pharma. // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p10
The article discusses the response of the Association of the British Pharmaceutical Industry's Director of Value and Access, Paul Catchpole, to the news that a new pricing scheme for drugs in England has been delayed by the National Institute for Health and Care Excellence until the fall of 2014.
- Maine's Rx Drug Pricing Measure Is Uncertain to Pass. // Chemical Market Reporter;03/19/2001, Vol. 259 Issue 12, p28
Examines the legal problem on the enactment of the proposed state legislation in Maine regarding the control of prescription drug prices. Terms of the proposed legislation; Claims of the Pharmaceutical Research and Manufacturers of America that the law is unconstitutional; Impact of the...